APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chronic Low Back Pain Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chronic Low Back Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173978010322 December 2025194 pages

Choose your research edition.

Industry ResearchChronic Low Back Pain Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Low Back Pain Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chronic Low Back Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Low Back Pain Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Low Back Pain Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Chronic Low Back Pain Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chronic Low Back Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Low Back Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Low Back Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chronic Low Back Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chronic Low Back Pain Drug include Takeda Pharmaceutical, Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Inc., Mylan, Eli Lilly and Company and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Low Back Pain Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Low Back Pain Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Low Back Pain Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Low Back Pain Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Low Back Pain Drug Segment by Company

Takeda Pharmaceutical

Teva Pharmaceuticals

Sanofi

Johnson & Johnson

Novartis

Merck & Co., Inc.

Mylan

Eli Lilly and Company

Pfizer

Endo Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Allergan

Chronic Low Back Pain Drug Segment by Type

Analgesic medications

Antidepressants

Anticonvulsants

Nonsteroidal anti-inflammatory drugs

Counter irritants

Chronic Low Back Pain Drug Segment by Application

Clinics

Hospitals

Ambulatory Surgical Centers

Others

Chronic Low Back Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Low Back Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Low Back Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Low Back Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Low Back Pain Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chronic Low Back Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chronic Low Back Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chronic Low Back Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chronic Low Back Pain Drug Industry Trends Table 2. Chronic Low Back Pain Drug Industry Drivers Table 3. Chronic Low Back Pain Drug Industry Opportunities and Challenges Table 4. Chronic Low Back Pain Drug Industry Restraints Table 5. Global Chronic Low Back Pain Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chronic Low Back Pain Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chronic Low Back Pain Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Chronic Low Back Pain Drug Sales Market Share by Manufacturers Table 9. Global Chronic Low Back Pain Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Chronic Low Back Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chronic Low Back Pain Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chronic Low Back Pain Drug Manufacturers, Product Type & Application Table 13. Global Chronic Low Back Pain Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Low Back Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Analgesic medications Table 17. Major Manufacturers of Antidepressants Table 18. Major Manufacturers of Anticonvulsants Table 19. Major Manufacturers of Nonsteroidal anti-inflammatory drugs Table 20. Major Manufacturers of Counter irritants Table 21. Global Chronic Low Back Pain Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Chronic Low Back Pain Drug Sales by Type (2021-2026) & (k units) Table 23. Global Chronic Low Back Pain Drug Sales by Type (2027-2032) & (k units) Table 24. Global Chronic Low Back Pain Drug Sales Market Share by Type (2021-2026) Table 25. Global Chronic Low Back Pain Drug Sales Market Share by Type (2027-2032) Table 26. Global Chronic Low Back Pain Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Chronic Low Back Pain Drug Revenue by Type (2021-2026) & (k units) Table 28. Global Chronic Low Back Pain Drug Revenue by Type (2027-2032) & (k units) Table 29. Global Chronic Low Back Pain Drug Revenue Market Share by Type (2021-2026) Table 30. Global Chronic Low Back Pain Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Hospitals Table 33. Major Manufacturers of Ambulatory Surgical Centers Table 34. Major Manufacturers of Others Table 35. Global Chronic Low Back Pain Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Chronic Low Back Pain Drug Sales by Application (2021-2026) & (k units) Table 37. Global Chronic Low Back Pain Drug Sales by Application (2027-2032) & (k units) Table 38. Global Chronic Low Back Pain Drug Sales Market Share by Application (2021-2026) Table 39. Global Chronic Low Back Pain Drug Sales Market Share by Application (2027-2032) Table 40. Global Chronic Low Back Pain Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Chronic Low Back Pain Drug Revenue by Application (2021-2026) & (k units) Table 42. Global Chronic Low Back Pain Drug Revenue by Application (2027-2032) & (k units) Table 43. Global Chronic Low Back Pain Drug Revenue Market Share by Application (2021-2026) Table 44. Global Chronic Low Back Pain Drug Revenue Market Share by Application (2027-2032) Table 45. Global Chronic Low Back Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Chronic Low Back Pain Drug Sales by Region (2021-2026) & (k units) Table 47. Global Chronic Low Back Pain Drug Sales Market Share by Region (2021-2026) Table 48. Global Chronic Low Back Pain Drug Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Chronic Low Back Pain Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Chronic Low Back Pain Drug Sales by Country (2021-2026) & (k units) Table 52. North America Chronic Low Back Pain Drug Sales by Country (2027-2032) & (k units) Table 53. Europe Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Chronic Low Back Pain Drug Sales by Country (2021-2026) & (k units) Table 55. Europe Chronic Low Back Pain Drug Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Chronic Low Back Pain Drug Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Chronic Low Back Pain Drug Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Chronic Low Back Pain Drug Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Chronic Low Back Pain Drug Sales by Country (2027-2032) & (k units) Table 62. Global Chronic Low Back Pain Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Chronic Low Back Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Chronic Low Back Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Chronic Low Back Pain Drug Revenue Market Share by Region (2021-2026) Table 66. Global Chronic Low Back Pain Drug Revenue Market Share by Region (2027-2032) Table 67. Takeda Pharmaceutical Company Information Table 68. Takeda Pharmaceutical Business Overview Table 69. Takeda Pharmaceutical Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Pharmaceutical Chronic Low Back Pain Drug Product Portfolio Table 71. Takeda Pharmaceutical Recent Development Table 72. Teva Pharmaceuticals Company Information Table 73. Teva Pharmaceuticals Business Overview Table 74. Teva Pharmaceuticals Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Pharmaceuticals Chronic Low Back Pain Drug Product Portfolio Table 76. Teva Pharmaceuticals Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Sanofi Chronic Low Back Pain Drug Product Portfolio Table 81. Sanofi Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Chronic Low Back Pain Drug Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Novartis Chronic Low Back Pain Drug Product Portfolio Table 91. Novartis Recent Development Table 92. Merck & Co., Inc. Company Information Table 93. Merck & Co., Inc. Business Overview Table 94. Merck & Co., Inc. Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Merck & Co., Inc. Chronic Low Back Pain Drug Product Portfolio Table 96. Merck & Co., Inc. Recent Development Table 97. Mylan Company Information Table 98. Mylan Business Overview Table 99. Mylan Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Mylan Chronic Low Back Pain Drug Product Portfolio Table 101. Mylan Recent Development Table 102. Eli Lilly and Company Company Information Table 103. Eli Lilly and Company Business Overview Table 104. Eli Lilly and Company Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Eli Lilly and Company Chronic Low Back Pain Drug Product Portfolio Table 106. Eli Lilly and Company Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Pfizer Chronic Low Back Pain Drug Product Portfolio Table 111. Pfizer Recent Development Table 112. Endo Pharmaceuticals Inc Company Information Table 113. Endo Pharmaceuticals Inc Business Overview Table 114. Endo Pharmaceuticals Inc Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Endo Pharmaceuticals Inc Chronic Low Back Pain Drug Product Portfolio Table 116. Endo Pharmaceuticals Inc Recent Development Table 117. Dr. Reddy's Laboratories Ltd Company Information Table 118. Dr. Reddy's Laboratories Ltd Business Overview Table 119. Dr. Reddy's Laboratories Ltd Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Dr. Reddy's Laboratories Ltd Chronic Low Back Pain Drug Product Portfolio Table 121. Dr. Reddy's Laboratories Ltd Recent Development Table 122. Allergan Company Information Table 123. Allergan Business Overview Table 124. Allergan Chronic Low Back Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Allergan Chronic Low Back Pain Drug Product Portfolio Table 126. Allergan Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Chronic Low Back Pain Drug Distributors List Table 130. Chronic Low Back Pain Drug Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Chronic Low Back Pain Drug Product Image Figure 2. Global Chronic Low Back Pain Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Low Back Pain Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Low Back Pain Drug Sales (2021-2032) & (k units) Figure 5. Global Chronic Low Back Pain Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chronic Low Back Pain Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Analgesic medications Image Figure 9. Antidepressants Image Figure 10. Anticonvulsants Image Figure 11. Nonsteroidal anti-inflammatory drugs Image Figure 12. Counter irritants Image Figure 13. Global Chronic Low Back Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Chronic Low Back Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Chronic Low Back Pain Drug Sales Market Share by Type (2021-2032) Figure 16. Global Chronic Low Back Pain Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Chronic Low Back Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Low Back Pain Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinics Image Figure 20. Hospitals Image Figure 21. Ambulatory Surgical Centers Image Figure 22. Others Image Figure 23. Global Chronic Low Back Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Chronic Low Back Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Chronic Low Back Pain Drug Sales Market Share by Application (2021-2032) Figure 26. Global Chronic Low Back Pain Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Chronic Low Back Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Chronic Low Back Pain Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Chronic Low Back Pain Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Chronic Low Back Pain Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Chronic Low Back Pain Drug Sales Market Share by Country (2021-2032) Figure 43. China Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Chronic Low Back Pain Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Chronic Low Back Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Chronic Low Back Pain Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Chronic Low Back Pain Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Chronic Low Back Pain Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Chronic Low Back Pain Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Chronic Low Back Pain Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Chronic Low Back Pain Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Chronic Low Back Pain Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Chronic Low Back Pain Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Analgesic medications
  • Antidepressants
  • Anticonvulsants
  • Nonsteroidal anti-inflammatory drugs
  • Counter irritants
Applications
  • Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co., Inc.
  • Mylan
  • Eli Lilly and Company
  • Pfizer
  • Endo Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chronic Low Back Pain Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chronic Low Back Pain Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chronic Low Back Pain Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chronic Low Back Pain Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chronic Low Back Pain Drug Market Dynamics
  1. 2.1 Chronic Low Back Pain Drug Industry Trends
  2. 2.2 Chronic Low Back Pain Drug Industry Drivers
  3. 2.3 Chronic Low Back Pain Drug Industry Opportunities and Challenges
  4. 2.4 Chronic Low Back Pain Drug Industry Restraints
3 Chronic Low Back Pain Drug Market by Manufacturers
  1. 3.1 Global Chronic Low Back Pain Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chronic Low Back Pain Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chronic Low Back Pain Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chronic Low Back Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chronic Low Back Pain Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chronic Low Back Pain Drug Manufacturers, Product Type & Application
  7. 3.7 Global Chronic Low Back Pain Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chronic Low Back Pain Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chronic Low Back Pain Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chronic Low Back Pain Drug Tier 1, Tier 2, and Tier 3
4 Chronic Low Back Pain Drug Market by Type
  1. 4.1 Chronic Low Back Pain Drug Type Introduction
  2. 4.1.1 Analgesic medications
  3. 4.1.2 Antidepressants
  4. 4.1.3 Anticonvulsants
  5. 4.1.4 Nonsteroidal anti-inflammatory drugs
  6. 4.1.5 Counter irritants
  7. 4.2 Global Chronic Low Back Pain Drug Sales by Type
  8. 4.2.1 Global Chronic Low Back Pain Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Chronic Low Back Pain Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Chronic Low Back Pain Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Chronic Low Back Pain Drug Revenue by Type
  12. 4.3.1 Global Chronic Low Back Pain Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Chronic Low Back Pain Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Chronic Low Back Pain Drug Revenue Market Share by Type (2021-2032)
5 Chronic Low Back Pain Drug Market by Application
  1. 5.1 Chronic Low Back Pain Drug Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Others
  6. 5.2 Global Chronic Low Back Pain Drug Sales by Application
  7. 5.2.1 Global Chronic Low Back Pain Drug Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chronic Low Back Pain Drug Sales by Application (2021-2032)
  9. 5.2.3 Global Chronic Low Back Pain Drug Sales Market Share by Application (2021-2032)
  10. 5.3 Global Chronic Low Back Pain Drug Revenue by Application
  11. 5.3.1 Global Chronic Low Back Pain Drug Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chronic Low Back Pain Drug Revenue by Application (2021-2032)
  13. 5.3.3 Global Chronic Low Back Pain Drug Revenue Market Share by Application (2021-2032)
6 Global Chronic Low Back Pain Drug Sales by Region
  1. 6.1 Global Chronic Low Back Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Low Back Pain Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Low Back Pain Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Chronic Low Back Pain Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chronic Low Back Pain Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chronic Low Back Pain Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chronic Low Back Pain Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chronic Low Back Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chronic Low Back Pain Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chronic Low Back Pain Drug Revenue by Region
  1. 7.1 Global Chronic Low Back Pain Drug Revenue by Region
  2. 7.1.1 Global Chronic Low Back Pain Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chronic Low Back Pain Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Chronic Low Back Pain Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Chronic Low Back Pain Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chronic Low Back Pain Drug Revenue (2021-2032)
  8. 7.2.2 North America Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chronic Low Back Pain Drug Revenue (2021-2032)
  11. 7.3.2 Europe Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chronic Low Back Pain Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chronic Low Back Pain Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chronic Low Back Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Chronic Low Back Pain Drug Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Teva Pharmaceuticals
  8. 8.2.1 Teva Pharmaceuticals Company Information
  9. 8.2.2 Teva Pharmaceuticals Business Overview
  10. 8.2.3 Teva Pharmaceuticals Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceuticals Chronic Low Back Pain Drug Product Portfolio
  12. 8.2.5 Teva Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Chronic Low Back Pain Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Chronic Low Back Pain Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Chronic Low Back Pain Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck & Co., Inc.
  32. 8.6.1 Merck & Co., Inc. Company Information
  33. 8.6.2 Merck & Co., Inc. Business Overview
  34. 8.6.3 Merck & Co., Inc. Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co., Inc. Chronic Low Back Pain Drug Product Portfolio
  36. 8.6.5 Merck & Co., Inc. Recent Developments
  37. 8.7 Mylan
  38. 8.7.1 Mylan Company Information
  39. 8.7.2 Mylan Business Overview
  40. 8.7.3 Mylan Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan Chronic Low Back Pain Drug Product Portfolio
  42. 8.7.5 Mylan Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Chronic Low Back Pain Drug Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Chronic Low Back Pain Drug Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Endo Pharmaceuticals Inc
  56. 8.10.1 Endo Pharmaceuticals Inc Company Information
  57. 8.10.2 Endo Pharmaceuticals Inc Business Overview
  58. 8.10.3 Endo Pharmaceuticals Inc Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Endo Pharmaceuticals Inc Chronic Low Back Pain Drug Product Portfolio
  60. 8.10.5 Endo Pharmaceuticals Inc Recent Developments
  61. 8.11 Dr. Reddy's Laboratories Ltd
  62. 8.11.1 Dr. Reddy's Laboratories Ltd Company Information
  63. 8.11.2 Dr. Reddy's Laboratories Ltd Business Overview
  64. 8.11.3 Dr. Reddy's Laboratories Ltd Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dr. Reddy's Laboratories Ltd Chronic Low Back Pain Drug Product Portfolio
  66. 8.11.5 Dr. Reddy's Laboratories Ltd Recent Developments
  67. 8.12 Allergan
  68. 8.12.1 Allergan Company Information
  69. 8.12.2 Allergan Business Overview
  70. 8.12.3 Allergan Chronic Low Back Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Allergan Chronic Low Back Pain Drug Product Portfolio
  72. 8.12.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Low Back Pain Drug Value Chain Analysis
  2. 9.1.1 Chronic Low Back Pain Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Low Back Pain Drug Production Mode & Process
  6. 9.2 Chronic Low Back Pain Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Low Back Pain Drug Distributors
  9. 9.2.3 Chronic Low Back Pain Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst